Spots Global Cancer Trial Database for bendamustine hydrochloride
Every month we try and update this database with for bendamustine hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | NCT00947388 | Recurrent Small... Refractory Chro... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Bendamustine Hy... Alemtuzumab | 18 Years - | Case Comprehensive Cancer Center | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01611090 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Bendamustine hy... Rituximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia | NCT03847727 | Chronic Lymphoc... | BR as Maintenan... | 18 Years - | Pirogov Russian National Research Medical University | |
| S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment | NCT00939328 | Leukemia | rituximab bendamustine hy... | 18 Years - | SWOG Cancer Research Network | |
| Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | NCT01141725 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Myelodysplastic... Untreated Adult... | bendamustine hy... idarubicin | 50 Years - | Fred Hutchinson Cancer Center | |
| Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) | NCT01108341 | Non-Hodgkin's L... | Bendamustine hy... Ofatumumab | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | NCT02240719 | Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Refractory Chro... Multiple Myelom... | everolimus bendamustine hy... | 18 Years - | University of California, Davis | |
| A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma | NCT00389051 | Non-Hodgkin's L... | bendamustine hy... | 20 Years - 75 Years | SymBio Pharmaceuticals | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia | NCT01109264 | Chronic Lymphoc... | Bendamustine hy... Chlorambucil | 18 Years - 75 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia | NCT03847727 | Chronic Lymphoc... | BR as Maintenan... | 18 Years - | Pirogov Russian National Research Medical University | |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | NCT01886872 | Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | Bendamustine Hy... Ibrutinib Laboratory Biom... Quality-of-Life... Rituximab | 65 Years - | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01369849 | Chronic Lymphoc... Recurrent Small... Refractory Chro... | Akt Inhibitor M... Bendamustine Hy... Laboratory Biom... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT02224729 | Stage I Multipl... Stage II Multip... Stage III Multi... | Bendamustine hy... Bortezomib Dexamethasone | 18 Years - | Thomas Jefferson University | |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | NCT02799147 | Leukemia, Acute... Acute Myeloid L... Mixed-Lineage A... | Allogeneic stem... Fludarabine mon... Busulfan Bendamustine | 18 Years - 60 Years | St. Petersburg State Pavlov Medical University | |
| A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment | NCT01596621 | Non-Hodgkin Lym... | Bendamustine hy... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01238146 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... | bendamustine hy... obatoclax mesyl... rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | NCT00823797 | Adult Anaplasti... Adult Anaplasti... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | Bendamustine Hy... Quality-of-Life... | 18 Years - | University of Washington | |
| S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma | NCT01412879 | Lymphoma | rituximab bendamustine hy... cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... leucovorin calc... methotrexate vincristine sul... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT02224729 | Stage I Multipl... Stage II Multip... Stage III Multi... | Bendamustine hy... Bortezomib Dexamethasone | 18 Years - | Thomas Jefferson University | |
| Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00274963 | Chronic Lymphoc... | bendamustine hy... mitoxantrone hy... | 18 Years - | German CLL Study Group | |
| Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | NCT01141725 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Myelodysplastic... Untreated Adult... | bendamustine hy... idarubicin | 50 Years - | Fred Hutchinson Cancer Center | |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) | NCT04942730 | Leukemia, Acute... Myeloid Leukemi... Biphenotypic Ac... Lymphoblastic L... Myelodysplastic... Myeloproliferat... | Fludarabine Bendamustine Hy... Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus 5Mg ... | 18 Years - 75 Years | St. Petersburg State Pavlov Medical University | |
| Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | NCT00901927 | Follicular Lymp... | Bendamustine Mitoxantrone Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma | NCT00612183 | Non-Hodgkin's L... Mantle Cell Lym... | bendamustine hy... | 20 Years - 75 Years | SymBio Pharmaceuticals | |
| Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | NCT03259529 | Diffuse Large B... | Bendamustine hy... Gemcitabine 500... Gemcitabine 700... Gemcitabine 100... Nivolumab Rituximab | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | NCT01415752 | Lymphoma Neurotoxicity Therapy-related... | rituximab bendamustine hy... bortezomib lenalidomide | 60 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT01049945 | Refractory Mult... | bendamustine hy... lenalidomide dexamethasone | 18 Years - | Mayo Clinic | |
| Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT01535924 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular L... Adult Nodular S... Recurrent Adult... | gemcitabine hyd... bendamustine hy... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma | NCT00987493 | Lymphoma | rituximab bendamustine hy... lenalidomide | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia | NCT01739491 | Chronic Lymphoc... | No intervention | 18 Years - | Janssen Pharmaceutica | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT04115631 | Liver Lymphoma Mantle Cell Lym... | Acalabrutinib Bendamustine Bendamustine Hy... Cytarabine Rituximab | 18 Years - 70 Years | Eastern Cooperative Oncology Group | |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01369849 | Chronic Lymphoc... Recurrent Small... Refractory Chro... | Akt Inhibitor M... Bendamustine Hy... Laboratory Biom... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma | NCT01286272 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Grade 3a Follic... | Bendamustine Hy... Bortezomib Fludeoxyglucose... Laboratory Biom... Ofatumumab Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | NCT01479842 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenstrom Mac... | BTK inhibitor P... rituximab bendamustine hy... pharmacogenomic... pharmacological... laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma | NCT02420210 | Diffuse Large B... | Bendamustine Hy... Obinutuzumab Dexamethasone Quality-of-Life... Laboratory Biom... | 70 Years - | University of Chicago | |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | NCT02240719 | Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Refractory Chro... Multiple Myelom... | everolimus bendamustine hy... | 18 Years - | University of California, Davis | |
| Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | NCT01479842 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenstrom Mac... | BTK inhibitor P... rituximab bendamustine hy... pharmacogenomic... pharmacological... laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia | NCT01109264 | Chronic Lymphoc... | Bendamustine hy... Chlorambucil | 18 Years - 75 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT02224729 | Stage I Multipl... Stage II Multip... Stage III Multi... | Bendamustine hy... Bortezomib Dexamethasone | 18 Years - | Thomas Jefferson University | |
| Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma | NCT00612183 | Non-Hodgkin's L... Mantle Cell Lym... | bendamustine hy... | 20 Years - 75 Years | SymBio Pharmaceuticals | |
| Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | NCT03259529 | Diffuse Large B... | Bendamustine hy... Gemcitabine 500... Gemcitabine 700... Gemcitabine 100... Nivolumab Rituximab | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | NCT03259529 | Diffuse Large B... | Bendamustine hy... Gemcitabine 500... Gemcitabine 700... Gemcitabine 100... Nivolumab Rituximab | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies | NCT04943757 | Myeloid Leukemi... Chronic Myeloid... Myelodysplastic... Myeloproliferat... | Bendamustine Hy... Cyclophosphamid | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
